Tag

Upadacitinib

All articles tagged with #upadacitinib

health1 month ago•5 min saved

Arthritis Drug Sparks Substantial Hair Growth in Severe Alopecia Areata

Two parallel Phase 3 trials (1,399 participants aged 12–64, including 118 adolescents) show the arthritis drug upadacitinib significantly boosts hair regrowth in severe alopecia areata over 24 weeks versus placebo, with about 45% (15 mg) to 55% (30 mg) achieving SALT ≤20 and up to 13–22.5% regrowing all scalp hair; benefits appeared by week 8 and were accompanied by quality-of-life gains, though long-term safety remains unknown and the trials were industry-sponsored by AbbVie.

via ScienceAlert|

#alopecia-areata #hair-regrowth #health

health1 month ago•12 min saved

Daily Arthritis Pill Sparks Major Hair Regrowth in Severe Alopecia Areata

Two Phase 3 UP-AA trials of the JAK1 inhibitor upadacitinib (Rinvoq) showed substantial hair regrowth in severe alopecia areata: 24 weeks of treatment yielded 45–55% of patients achieving at least 80% scalp coverage and up to 23% reaching complete regrowth, with improvements continuing through a 52‑week extension; Europe approved the drug for this use in 2026 and the FDA decision in the US was pending at that time; safety matched other JAK inhibitors, necessitating monitoring.

via intelligentliving.co|

#alopecia-areata #clinical-trial #health

science1 month ago•6 min saved

Arthritis drug sparks notable hair regrowth in alopecia trials

An oral arthritis medication called upadacitinib demonstrated substantial hair regrowth in two international trials for severe alopecia areata, with about half of participants achieving at least 80% scalp coverage after 24 weeks; some reached complete restoration. While promising, results vary by patient and longer-term effects and safety still need assessment.

via Interesting Engineering|

#alopecia-areata #arthritis-drug #autoimmune-disease

health1 month ago•5 min saved

Rheumatoid arthritis drug shows promise for regrowing hair in alopecia areata

A phase 3 trial found that the JAK inhibitor upadacitinib, used to treat rheumatoid arthritis, regrew hair in about half to just over half of participants with severe alopecia areata within 24 weeks, with 80% scalp coverage achievable at the 30 mg dose. Eyebrows and eyelashes also improved, and participants reported better emotional and social well-being. The drug is approved for severe alopecia areata in Europe and is under FDA review in the U.S.; longer-term safety and durability data are still needed to inform routine use.

via Medical News Today|

#alopecia-areata #hair-regrowth #health

health1 month ago•5 min saved

Daily Pill Shows Color Return in Vitiligo Patients (Early Trials)

In two 48-week, placebo-controlled trials, the daily JAK inhibitor upadacitinib helped some people with generalized vitiligo regain skin color across the face and body. About 23–25% on the drug reached at least 75% facial color (vs 6–7% placebo), 19–21% regained half their color elsewhere, and 14% achieved 90% facial color, with improvements persisting beyond 48 weeks. While promising, most participants did not reach the main facial target and long-term durability and safety remain uncertain. The EU has approved the drug for eligible patients aged 12+, but darker-skinned groups were underrepresented; common side effects included infections, acne, headaches, and shingles. Ongoing follow-up for up to 112 more weeks aims to clarify lasting benefits.

via ScienceAlert|

#health #jak-inhibitors #randomized-controlled-trial

health1 month ago•4 min saved

Arthritis drug prompts remarkable hair regrowth in severe alopecia areata, study finds

Six-month study shows the arthritis drug upadacitinib (Rinvoq) can trigger dramatic hair regrowth in severe alopecia areata, with 45-55% of patients reaching 80% scalp coverage (more at higher doses) and notable eyebrow/eyelash restoration; the treatment is off-label for alopecia in the US as AbbVie seeks FDA approval, while the EU recently approved it.

via New York Post|

#alopecia-areata #hair-growth #health

health3 years ago•3 min saved

Advancing Skin Health: Experts Call for Consensus Human Skin Cell Atlas

In August 2023, experts at the Asembia Specialty Pharmacy Summit emphasized the importance of listening to patients and caregivers when treating pediatric atopic dermatitis (AD), a skin condition characterized by inflamed and itchy rashes. Sleep disturbances and anxiety are common among caregivers, highlighting the need for comprehensive care. Meanwhile, a study found that upadacitinib maintained its efficacy for 3 years in patients with psoriatic arthritis, with no new safety concerns identified. Additionally, lebrikizumab showed promising results in improving or clearing the skin of adult and adolescent patients with moderate to severe AD.

via Pharmacy Times|

#health #lebrikizumab #pediatric-atopic-dermatitis